Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis. - Wikidata - awgldk - TriplyDB

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

http://www.wikidata.org/entity/Q34620355

about

Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo.

P2860

Q30432272-6C4A37FC-92D5-4A37-9EF8-3D9A5B99D00A

P2860

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

http://www.wikidata.org/entity/Q34620355

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

@ast

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

@en

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

@nl

type

label

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

@ast

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

@en

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

@nl

prefLabel

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

@ast

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

@en

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

@nl

P1433

Q34620355-5BE01F59-8B38-485D-83A5-B16027901CB2

P1476

Q34620355-E47061FF-1183-4C7C-8CA4-1570BA2C845E

P2093

Q34620355-03F73215-0C05-4126-84AD-7C745DC7DBF9

Q34620355-7B2675E7-1908-4959-A6FA-F152FDB0492C

P2860

Q34620355-0A677032-0243-4CD5-823F-9CD032AB06DB

Q34620355-188AB9C1-9D7C-40F4-891B-3BF5AA9966E3

Q34620355-189CCAFB-8A72-4DFB-9666-EE625BA45F8B

Q34620355-261F8DFC-971B-4DBC-9088-487C92718C7D

Q34620355-32D9978E-7F7B-454B-8FB3-A783850A04B3

Q34620355-5DA82FEB-87F7-4B32-83E3-77EC9A070DB6

Q34620355-6473E898-5CBD-435E-ADE4-4AE3FEE54F45

Q34620355-6485D053-57A7-4789-9EE4-4A96F746BE81

Q34620355-6A8F4DE8-426F-42F3-A942-1492E48AEF5B

Q34620355-750DF264-5031-432B-805D-5F1B94FDC5AE

P304

Q34620355-D2636CFD-C97C-4980-BB61-554EA47BE961

P31

Q34620355-80FBBF89-B1E8-4A44-997A-5A2B6C04D348

P407

Q34620355-815DD92C-BD6D-42A5-93C8-D739C91B9F75

P478

Q34620355-1F69BEF2-6CB7-4F2B-A8B5-3373C88A17C1

P577

Q34620355-0A39D392-D097-47C8-AF0F-A9E9AE38F50F

P698

Q34620355-BF76874B-138C-4112-99C5-9C75A193E0DB

P932

Q34620355-D789FAF0-332C-4E22-8A49-C2523CA228EB

P1433

Clinical, Cosmetic and Investigational Dermatology

P1476

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis.

@en

P2093

Alice B Gottlieb

http://www.w3.org/2001/XMLSchema#string

Melissa A Michelon

http://www.w3.org/2001/XMLSchema#string

P2860

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis.

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.

Dermatological complications and safety of anti-TNF treatments.

Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation.

The prevalence of psoriatic arthritis in people with psoriasis.

Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.

P304

79-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21437062

http://www.w3.org/2001/XMLSchema#string

P932

3047949

http://www.w3.org/2001/XMLSchema#string